Physician profile
Bradford L Ebright
NPI 1053316158
$3,758.44
in general payments reported to CMS, 2019-2025
30 companies · $708 in 2025
The $708 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $445 · 2021: $596 · 2022: $528 · 2023: $559 · 2024: $532 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $558.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $520.55 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $481.58 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $396.71 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.33 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $275.95 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.57 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $120.12 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $117.27 | 2021-2025 | Eliquis, Camzyos |
| Amgen INC. | $80.45 | 2020-2025 | Krystexxa, Otezla, Repatha |
| Amarin Pharma, INC. | $78.35 | 2020-2022 | |
| Glaxosmithkline, LLC. | $72.35 | 2020-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $61.24 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $50.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $46.28 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.19 | 2021-2022 | |
| Sanofi Pasteur INC. | $37.95 | 2019-2025 | |
| Dexcom, INC. | $35.03 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $30.75 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $25.56 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $23.98 | 2019 | |
| Corcept Therapeutics | $23.08 | 2022 | |
| Astellas Pharma US INC | $22.57 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $21.40 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.01 | 2019 | |
| Abbott Laboratories | $18.57 | 2024 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $18.09 | 2023 | Symtuza |
| Eisai INC. | $17.54 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.51 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradford Ebright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.